Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW0813 vs Eylea in diabetic macular edema
CTR20212636Phase 3Completed
- Sponsor
- Maiwei Biotech
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 9MW0813 in diabetic macular edema (DME), sponsored by Maiwei Biotech. Started Oct 2021; status: completed.
02
Drugs
9MW0813
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20212636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212636.